Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...